Nxera Pharma Co., Ltd.
Announcement of License Agreement for GPCR-Targeted Program
Nexera Pharma has entered into an exclusive license agreement for a GPCR-targeted program with a venture company established by a European VC, acquiring shares in the company and rights to receive milestone and royalty payments.
Key Figures
- Agreement Date: 2026-02-12
- Target Program: GPCR-targeted program (exclusive license worldwide excluding Japan and parts of APAC)
- Impact on FY2026 Results: Under review
AI要約
Overview of the License Agreement
Nexera Pharma Corporation has concluded an exclusive license agreement for a GPCR-targeted program with a venture company established by a prominent European venture capital firm. Under the contract, Nexera Pharma is granted rights for development, manufacturing, and commercialization worldwide excluding Japan and parts of the Asia-Pacific region, while simultaneously acquiring shares in the venture company. The company also has rights to receive milestone rewards and royalties based on sales; however, the detailed terms of the agreement are undisclosed.
Outlook and Impact
Through this agreement, Nexera Pharma aims to maximize the value of the GPCR-targeted program by partnering with an overseas partner possessing development promotion capabilities and funding functions. Nexera Pharma may also participate in the company’s planned Series A funding round alongside the overseas VC. The impact on the consolidated results for the fiscal year ending December 2026 is currently under review, and any matters requiring disclosure will be promptly announced.
